Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1975 3
1976 1
1977 1
1983 3
1987 1
1988 3
1989 2
1990 3
1991 3
1992 1
1993 5
1994 4
1995 4
1996 1
1997 8
1998 5
1999 7
2000 10
2001 4
2002 8
2003 4
2004 3
2005 4
2006 4
2007 6
2008 12
2009 7
2010 4
2011 11
2012 7
2013 9
2014 18
2015 11
2016 16
2017 10
2018 20
2019 14
2020 16
2021 18
2022 21
2023 11
2024 13
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies.
Taylor LE, Swerdfeger AL, Eslick GD. Taylor LE, et al. Vaccine. 2014 Jun 17;32(29):3623-9. doi: 10.1016/j.vaccine.2014.04.085. Epub 2014 May 9. Vaccine. 2014. PMID: 24814559
There has been enormous debate regarding the possibility of a link between childhood vaccinations and the subsequent development of autism. This has in recent times become a major public health issue with vaccine preventable diseases increasing in the communi …
There has been enormous debate regarding the possibility of a link between childhood vaccinations and the subsequent development of a …
Measles, mumps, and rubella vaccine at age 6 months and hospitalisation for infection before age 12 months: randomised controlled trial.
Zimakoff AC, Jensen A, Vittrup DM, Herlufsen EH, Sørensen JK, Malon M, Svensson J, Stensballe LG. Zimakoff AC, et al. BMJ. 2023 Jun 7;381:e072724. doi: 10.1136/bmj-2022-072724. BMJ. 2023. PMID: 37286215 Free PMC article. Clinical Trial.
OBJECTIVE: To test for potential non-specific effects of an additional, early measles, mumps, and rubella (MMR) vaccine at age 5-7 months on risk of infection related hospitalisation before age 12 months. ...In the intention-to-treat analysis the rate of hospitalisa …
OBJECTIVE: To test for potential non-specific effects of an additional, early measles, mumps, and rubella (MMR) vaccine at age …
Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Di Pietrantonj C, et al. Cochrane Database Syst Rev. 2020 Apr 20;4(4):CD004407. doi: 10.1002/14651858.CD004407.pub4. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Nov 22;11:CD004407. doi: 10.1002/14651858.CD004407.pub5. PMID: 32309885 Free PMC article. Updated.
OBJECTIVES: To assess the effectiveness, safety, and long- and short-term adverse effects associated with the trivalent vaccine, containing measles, rubella, mumps strains (MMR), or concurrent administration of MMR vaccine and varicella vaccine (MMR+V) …
OBJECTIVES: To assess the effectiveness, safety, and long- and short-term adverse effects associated with the trivalent vaccine, cont …
A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
Adigweme I, Yisa M, Ooko M, Akpalu E, Bruce A, Donkor S, Jarju LB, Danso B, Mendy A, Jeffries D, Segonds-Pichon A, Njie A, Crooke S, El-Badry E, Johnstone H, Royals M, Goodson JL, Prausnitz MR, McAllister DV, Rota PA, Henry S, Clarke E. Adigweme I, et al. Lancet. 2024 May 11;403(10439):1879-1892. doi: 10.1016/S0140-6736(24)00532-4. Epub 2024 Apr 29. Lancet. 2024. PMID: 38697170 Free PMC article. Clinical Trial.
This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children. METHODS: This single-centre, phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation tr …
This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (M …
Immunogenicity and safety of concomitant administration of the sabin-strain-based inactivated poliovirus vaccine, the diphtheria-tetanus-acellular pertussis vaccine, and measles-mumps-rubella vaccine to healthy infants aged 18 months in China.
Xu Y, Chen H, Wang B, Zhu X, Luo L, Wang S, Xiao Y, Wang H, Ma R, Liu S, Yan L, Li X, Chen D, Su Y, Chai Y, Fu J, Mao X, Cao J, Sun P, Tang F, Sun X, Wang Z, Yang X. Xu Y, et al. Int J Infect Dis. 2023 Dec;137:9-15. doi: 10.1016/j.ijid.2023.10.006. Epub 2023 Oct 11. Int J Infect Dis. 2023. PMID: 37832931 Free article. Clinical Trial.
OBJECTIVES: During the COVID-19 pandemic, there was a decline in vaccine coverage, and the implementation of combined vaccines and co-administration strategies emerged as potential solutions to alleviate this predicament. Our objective is to delve into the concurren …
OBJECTIVES: During the COVID-19 pandemic, there was a decline in vaccine coverage, and the implementation of combined vaccines …
Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis.
Nic Lochlainn LM, de Gier B, van der Maas N, van Binnendijk R, Strebel PM, Goodman T, de Melker HE, Moss WJ, Hahné SJM. Nic Lochlainn LM, et al. Lancet Infect Dis. 2019 Nov;19(11):1246-1254. doi: 10.1016/S1473-3099(19)30396-2. Epub 2019 Sep 20. Lancet Infect Dis. 2019. PMID: 31548081 Free PMC article.
BACKGROUND: Vaccinating infants with a first dose of measles-containing vaccine (MCV1) before 9 months of age in high-risk settings has the potential to reduce measles-related morbidity and mortality. However, there is concern that early vaccination …
BACKGROUND: Vaccinating infants with a first dose of measles-containing vaccine (MCV1) before 9 months of age in high-r …
Measles vaccine effectiveness in African children: a systematic review and meta-analysis.
Endalamaw D, Nibret E, Munshea A, Mekonnen F, Tadesse S, Zeru T, Tefera M, Yismaw G. Endalamaw D, et al. BMC Infect Dis. 2024 Nov 21;24(1):1330. doi: 10.1186/s12879-024-10239-w. BMC Infect Dis. 2024. PMID: 39574018 Free PMC article.
INTRODUCTION: Measles is an extremely contagious viral disease that can be prevented through vaccination. ...The disease spreads through respiratory droplets and continues to pose a significant public health challenge, especially in Africa, despite vaccina …
INTRODUCTION: Measles is an extremely contagious viral disease that can be prevented through vaccination. ...The diseas …
MMR vaccination induces trained immunity via functional and metabolic reprogramming of gammadelta T cells.
Röring RJ, Debisarun PA, Botey-Bataller J, Suen TK, Bulut Ö, Kilic G, Koeken VA, Sarlea A, Bahrar H, Dijkstra H, Lemmers H, Gössling KL, Rüchel N, Ostermann PN, Müller L, Schaal H, Adams O, Borkhardt A, Ariyurek Y, de Meijer EJ, Kloet SL, Ten Oever J, Placek K, Li Y, Netea MG. Röring RJ, et al. J Clin Invest. 2024 Jan 30;134(7):e170848. doi: 10.1172/JCI170848. J Clin Invest. 2024. PMID: 38290093 Free PMC article. Clinical Trial.
The measles, mumps, and rubella (MMR) vaccine protects against all-cause mortality in children, but the immunological mechanisms mediating these effects are poorly known. ...Monocyte function was not altered by MMR vaccination. In contrast, the function of ga …
The measles, mumps, and rubella (MMR) vaccine protects against all-cause mortality in children, but the immunological mechanis …
The mortality effects of disregarding the strategy to save doses of measles vaccine: a cluster-randomised trial in Guinea-Bissau.
Byberg S, Aaby P, Rodrigues A, Stabell Benn C, Fisker AB. Byberg S, et al. BMJ Glob Health. 2021 May;6(5):e004328. doi: 10.1136/bmjgh-2020-004328. BMJ Glob Health. 2021. PMID: 33941513 Free PMC article. Clinical Trial.
INTRODUCTION: Measles vaccine (MV) may improve health beyond measles protection. To avoid wastage from multi-dose vials, children in Guinea-Bissau are only measles vaccinated when aged 9-11 months and when six or more children are present. ... …
INTRODUCTION: Measles vaccine (MV) may improve health beyond measles protection. To avoid wastage from multi-dose vials …
Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.
Ma SJ, Li X, Xiong YQ, Yao AL, Chen Q. Ma SJ, et al. Medicine (Baltimore). 2015 Nov;94(44):e1721. doi: 10.1097/MD.0000000000001721. Medicine (Baltimore). 2015. PMID: 26554769 Free PMC article. Review.
A combined measles-mumps-rubella-varicella (MMRV) vaccine is expected to facilitate universal immunization against these 4 diseases. ...Nineteen RCTs compared single MMRV dose with measles-mumps-rubella vaccine with or without varicella vaccine …
A combined measles-mumps-rubella-varicella (MMRV) vaccine is expected to facilitate universal immunization against these 4 dis …
305 results